Aprea Therapeutics, Inc. (APRE) shareholders
Close on Nov 17, 2026Market cap $5.71MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ryan Wilder Joint filing with Vestal Point Capital, LP (9.90%) | 22,654,832 | 9.90% | 13G (passive) | Mar 31, 2026 |
| Squadron Capital Management LLC Joint filing with Squadron Master Fund LP (9.90%), William Blank (9.90%) and 1 more | 1,271,081 | 9.90% | 13G (passive) | Mar 30, 2026 |
| Soleus GP, LLC Joint filing with Soleus Private Equity Fund III, L.P. (9.99%), Soleus Private Equity GP III, LLC (9.99%) and 6 more | 1,271,080 | 9.99% | 13G (passive) | Apr 1, 2026 |
| Orin Hirschman Joint filing with AIGH Capital Management LLC (9.90%) | 1,186,294 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| AIGH Capital Management LLC Joint filing with Orin Hirschman (9.90%) | 651,747 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Jon M. Plexico Joint filing with Stonepine Capital Management, LLC (5.10%), Stonepine Capital, L.P. (5.10%) and 1 more | 286,395 | 5.10% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of APRE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 1,015,541 | 8.07% | $814.77K | – | 0.05% |
| Nantahala Capital Management, LLC | 411,520 | 3.27% | $330.16K | +205,760 | 0.01% |
| Vestal Point Capital, LP | 350,000 | 2.78% | $280.81K | – | 0.01% |
| Sphera Funds Management Ltd. | 270,000 | 2.14% | $216.62K | – | 0.03% |
| Renaissance Technologies LLC | 105,800 | 0.84% | $84.88K | +80,700 | 0.00% |
| Geode Capital Management, LLC | 74,869 | 0.59% | $60.07K | −44,262 | 0.00% |
| Citadel Advisors LLC | 58,600 | 0.47% | $47.02K | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 45,211 | 0.36% | $36.27K | +5,394 | 0.00% |
| Diadema Partners LP | 44,907 | 0.36% | $36.03K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 38,464 | 0.31% | $30.85K | – | 0.00% |
| Susquehanna International Group, Llp | 34,939 | 0.28% | $28.03K | +21,921 | 0.00% |
| Morgan Stanley | 25,830 | 0.21% | $20.72K | +3,500 | 0.00% |
| Vanguard Capital Management LLC | 22,882 | 0.18% | $18.35K | +3,260 | 0.00% |
| LPL Financial LLC | 16,052 | 0.13% | $12.88K | −5,000 | 0.00% |
| HighTower Advisors, LLC | 13,864 | 0.11% | $11.12K | – | 0.00% |
| Northern Trust Corp | 13,705 | 0.11% | $11.00K | New | 0.00% |
| Persistent Asset Partners Ltd | 11,490 | 0.09% | $9.22K | New | 0.00% |
| XTX Topco Ltd | 10,565 | 0.08% | $8.48K | New | 0.00% |
| BlackRock, Inc. | 7,173 | 0.06% | $5.76K | −1,331 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,590 | 0.03% | $2.88K | −1,537 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 28 | 3M | 20.5% | 8 / 6 | 5 / 2 | 0M | 0M |
| Q1 2026 | 22 | 2M | 17.8% | 7 / 4 | 5 / 6 | 1M | 1M |
| Q4 2025 | 22 | 2M | 13.5% | 5 / 5 | 6 / 6 | 1M | 1M |
| Q3 2025 | 23 | 2M | 12.9% | 2 / 5 | 6 / 2 | 0M | 0M |
| Q2 2025 | 23 | 2M | 14.4% | 1 / 7 | 4 / 4 | 0M | 0M |
| Q1 2025 | 26 | 2M | 15.5% | 1 / 4 | 7 / 1 | 0M | 0M |
| Q4 2024 | 26 | 2M | 16.5% | 5 / 5 | 5 / 1 | 0M | 0M |
| Q3 2024 | 22 | 2M | 17.0% | 1 / 6 | 5 / 6 | 0M | 0M |
| Q2 2024 | 28 | 2M | 18.2% | 7 / 6 | 4 / 3 | 1M | 0M |
| Q1 2024 | 24 | 2M | 13.3% | 7 / 6 | 3 / 3 | 1M | 0M |
| Q4 2023 | 20 | 1M | 7.5% | 1 / 6 | 3 / 2 | 0M | 0M |
| Q3 2023 | 21 | 1M | 7.0% | 4 / 2 | 6 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
6 funds held APRE in Q2 2026, 17% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of APRE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 80,925 | 0.64% | $72.23K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 19,622 | 0.16% | $15.74K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 7,197 | 0.06% | $6.42K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 5,851 | 0.05% | $5.22K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,100 | 0.02% | $1.87K | 0.00% | May 31, 2026 |
| Diversified Equity Alpha Master Portfolio | 289 | 0.00% | $232 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Oren Gilad | President/CEO, Director | 395,695 | 3.14% | Mar 16, 2026 |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | 43,528 | 0.35% | Apr 1, 2026 |
| Jean-Pierre Bizzari | Director | 4,180 | 0.03% | Jun 17, 2026 |
| Bernd R. Seizinger | Director | 48,910 | 0.39% | Jun 17, 2026 |
| Richard Peters | Director | 6,254 | 0.05% | Jun 17, 2026 |
| Gabriela Gruia | Director | 4,180 | 0.03% | Jun 17, 2026 |
| Rifat Pamukcu | Director | 22,689 | 0.18% | Jun 17, 2026 |
| Michael Grissinger | Director | 6,024 | 0.05% | Jun 17, 2026 |
| Marc Duey | Director | 259,892 | 2.06% | Jun 17, 2026 |
| John B. Henneman Iii | Director | 13,364 | 0.11% | Jun 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Grissinger Director | Jun 16, 2026 | Award | +3,135 | – | – | 6,024 |
| Marc Duey Director | Jun 16, 2026 | Award | +3,135 | – | – | 259,290 |
| Richard Peters Director | Jun 16, 2026 | Award | +3,135 | – | – | 6,254 |
| Rifat Pamukcu Director | Jun 16, 2026 | Award | +3,135 | – | – | 8,581 |
| John B. Henneman Iii Director | Jun 16, 2026 | Award | +3,135 | – | – | 13,364 |
| Jean-Pierre Bizzari Director | Jun 16, 2026 | Award | +3,135 | – | – | 4,180 |
| Bernd R. Seizinger Director | Jun 16, 2026 | Award | +3,135 | – | – | 48,910 |
| Gabriela Gruia Director | Jun 16, 2026 | Award | +3,135 | – | – | 4,180 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Mar 12, 2026 | Award | +10,095 | – | – | 43,528 |
| Oren Gilad President/CEO, Director | Mar 12, 2026 | Award | +20,175 | – | – | 393,895 |
| Oren Gilad President/CEO, Director | Jan 30, 2026 | Buy | +28,100 | $0.89 | $25.01K | 373,720 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Jan 30, 2026 | Buy | +5,700 | $0.89 | $5.07K | 33,433 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Dec 10, 2025 | Buy | +5,000 | $1.17 | $5.85K | 27,733 |
| Marc Duey Director | Dec 10, 2025 | Buy | +21,459 | $1.17 | $25.11K | 256,155 |
| Marc Duey Director | Jun 5, 2025 | Award | +1,045 | – | – | 234,696 |
| John B. Henneman Iii Director | Jun 5, 2025 | Award | +1,045 | – | – | 10,229 |
| Michael Grissinger Director | Jun 5, 2025 | Award | +1,045 | – | – | 2,889 |
| Rifat Pamukcu Director | Jun 5, 2025 | Award | +1,045 | – | – | 5,446 |
| Bernd R. Seizinger Director | Jun 5, 2025 | Award | +1,045 | – | – | 45,775 |
| Gabriela Gruia Director | Jun 5, 2025 | Award | +1,045 | – | – | 1,045 |
| Jean-Pierre Bizzari Director | Jun 5, 2025 | Award | +1,045 | – | – | 1,045 |
| Richard Peters Director | Jun 5, 2025 | Award | +1,045 | – | – | 3,119 |
| Oren Gilad President/CEO, Director | Apr 3, 2025 | Buy | +3,003 | $1.87 | $5.62K | 343,123 |
| Oren Gilad President/CEO, Director | Apr 3, 2025 | Buy | +2,497 | $1.80 | $4.49K | 345,620 |
| Oren Gilad President/CEO, Director | Mar 27, 2025 | Award | +6,725 | – | – | 340,120 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Mar 27, 2025 | Award | +3,365 | – | – | 22,733 |
| Oren Gilad President/CEO, Director | Oct 23, 2024 | Buy | +500 | $3.92 | $1.96K | 333,395 |
| Marc Duey Director | Oct 18, 2024 | Sale | −6,462 | $4.58 | $29.60K | 233,651 |
| Marc Duey Director | Oct 16, 2024 | Buy | +30,000 | $4.39 | $131.70K | 240,113 |
| Oren Gilad President/CEO, Director | Oct 15, 2024 | Buy | +250 | $2.90 | $725 | 332,895 |
| Marc Duey Director | Oct 14, 2024 | Buy | +190 | $2.58 | $490 | 210,113 |
| Oren Gilad President/CEO, Director | Oct 14, 2024 | Buy | +1,000 | $2.59 | $2.59K | 332,645 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Oct 11, 2024 | Buy | +50 | $2.46 | $123 | 19,368 |
| Bernd R. Seizinger Director | Oct 11, 2024 | Buy | +10,000 | $2.68 | $26.80K | 44,730 |
| Oren Gilad President/CEO, Director | Oct 10, 2024 | Buy | +150 | $2.54 | $381 | 331,645 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Oct 10, 2024 | Buy | +450 | $2.61 | $1.17K | 19,318 |
| Rifat Pamukcu Director | Jun 20, 2024 | Award | +1,045 | – | – | 4,401 |
| Bernd R. Seizinger Director | Jun 20, 2024 | Award | +1,045 | – | – | 34,730 |
| Marc Duey Director | Jun 20, 2024 | Award | +1,045 | – | – | 209,923 |
| John B. Henneman Iii Director | Jun 20, 2024 | Award | +1,045 | – | – | 9,184 |
| Richard Peters Director | Jun 20, 2024 | Award | +1,045 | – | – | 2,074 |
| Michael Grissinger Director | Jun 20, 2024 | Award | +1,045 | – | – | 1,844 |
| Nadeem Q. Mirza Chief Medical Officer | May 1, 2024 | Award | +6,730 | – | – | 6,730 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Mar 28, 2024 | Award | +3,365 | – | – | 18,868 |
| Oren Gilad President, CEO, Director | Mar 28, 2024 | Award | +6,725 | – | – | 331,495 |
| John B. Henneman Iii Director | Mar 13, 2024 | Buy | +6,860 | $7.29 | $50.01K | 8,139 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Mar 13, 2024 | Buy | +1,010 | $7.29 | $7.36K | 15,503 |
| Oren Gilad President, CEO, Director | Mar 13, 2024 | Buy | +2,000 | $7.29 | $14.58K | 324,770 |
| Bernd R. Seizinger Director | Mar 13, 2024 | Buy | +6,860 | $7.29 | $50.01K | 33,685 |
| Bernd R. Seizinger Director | Aug 23, 2023 | Award | +500 | – | – | 26,825 |
| Richard Peters Director | Aug 23, 2023 | Award | +500 | – | – | 1,029 |
| Rifat Pamukcu Director | Aug 23, 2023 | Award | +500 | – | – | 3,356 |
| John B. Henneman Iii Director | Aug 23, 2023 | Award | +500 | – | – | 1,279 |
| Michael Grissinger Director | Aug 23, 2023 | Award | +500 | – | – | 799 |
| Marc Duey Director | Aug 23, 2023 | Award | +500 | – | – | 208,878 |
| Bernd R. Seizinger Director | Jun 7, 2023 | Buy | +6,029 | $3.68 | $22.19K | 26,325 |
| Bernd R. Seizinger Director | Jun 6, 2023 | Buy | +4,068 | $3.63 | $14.77K | 20,296 |
| Oren Gilad President, CEO, Director | Mar 9, 2023 | Award | +4,000 | – | – | 322,770 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Feb 27, 2023 | Award | +1,000 | $5.25 | $5.25K | 14,493 |
| John P. Hamill SrVP/CFO/Prin. Fin&Acctg. Off | Jan 30, 2023 | Award | +269,879 | – | – | 269,879 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aprea Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,375 shares on Aug 27, 2026 over the last 90 days.
See a number that looks wrong?